Singapore, April 2 -- US-based Apollomics Inc., a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and Taiwan-based LaunXP International Co., an affiliate of LaunXP Biomedical Co. have entered into an agreement for the development and commercialisation in Asia (excluding mainland China, Hong Kong and Macau) (the LaunXP Territory) of vebreltinib, Apollomics' proprietary c-Met inhibitor, in combination with an EGFR inhibitor (EGFRi) for the treatment of non-small cell lung cancer (NSCLC). The EGFRi class of targeted kinase inhibitors is currently a foundational targeted therapy for the treatment of NSCLC and other tumor types.

"EGFRi is...